Iovance Biotherapeutics is trading 10% up at $7.74, as biotechnology stocks rally broadly after Moderna and Merck reported positive Phase 3 melanoma-vaccine results.
- The trial met goals for reducing recurrence and preventing cancer spread, sending Moderna sharply higher and lifting sentiment across oncology and biotechnology stocks.
- No fresh company-specific announcement for August 19, 2026 appears to explain the move; earlier Q2 results remain supportive background.